DV
Dividend Vision

IMDX — Insight Molecular Diagnostics Inc.

Insight Molecular Diagnostics Inc. (IMDX)

Total return is -97.3% over the past 10.6 years, 444.5 points behind SPY at 347.2%. Its deepest 1-year drawdown was 69.9%.

Insight Molecular Diagnostics Inc. operates as a precision diagnostics company developing and commercializing laboratory-developed tests and kitted tests focused on oncology and transplant monitoring, including blood-based cancer treatment response monitoring tools, immunotherapy response prediction tests, and transplant rejection risk assessments. The company does not currently distribute dividends. This security appeals to growth-oriented investors seeking exposure to the molecular diagnostics and precision medicine sector, as the company is pre-revenue or in early commercialization stages focused on test development and market adoption rather than current income generation.

IMDX key facts

Asset type
Stock
Asset class
Equity
Inception date
12/30/2015
Last close
$4.32
Market cap
$161,450,848
Average volume
331600.0
Beta
1.765
Payout ratio
0.0
Forward P/E
0.0
EPS
$-1.57